I. Tannock

404 total citations
23 papers, 311 citations indexed

About

I. Tannock is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, I. Tannock has authored 23 papers receiving a total of 311 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Pulmonary and Respiratory Medicine, 10 papers in Oncology and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in I. Tannock's work include Prostate Cancer Treatment and Research (7 papers), Cancer Treatment and Pharmacology (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). I. Tannock is often cited by papers focused on Prostate Cancer Treatment and Research (7 papers), Cancer Treatment and Pharmacology (5 papers) and Radiopharmaceutical Chemistry and Applications (4 papers). I. Tannock collaborates with scholars based in Canada, France and United States. I. Tannock's co-authors include Gordon Winocur, Janette L. Vardy, Lígia Regina Franco Sansigolo Kerr, Malcolm A. Binns, Margaret Moore, Fred Saad, Bernhard J. Eigl, Joseph D. Powers, Evan Y. Yu and Melissa M. Moore and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Cancer Research.

In The Last Decade

I. Tannock

21 papers receiving 294 citations

Peers

Countries citing papers authored by I. Tannock

Since Specialization

Citations

This map shows the geographic impact of I. Tannock's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by I. Tannock with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites I. Tannock more than expected).

Fields of papers citing papers by I. Tannock

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by I. Tannock. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by I. Tannock. The network helps show where I. Tannock may publish in the future.

Co-authorship network of co-authors of I. Tannock

This figure shows the co-authorship network connecting the top 25 collaborators of I. Tannock. A scholar is included among the top collaborators of I. Tannock based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with I. Tannock. I. Tannock is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Phase II study of individualized sunitinib as first-line therapy for metastatic renal cell cancer (mRCC). 2015 ·Journal of Clinical Oncology ·Georg A. Bjarnason, Jennifer J. Knox, Christian Kollmannsberger, Denis Soulières, D. Scott Ernst, Christina M. Canil, Eric Winquist, Paweł Zalewski, Sébastien J. Hotte, Scott North, Daniel Yick Chin Heng, Robyn Jane Macfarlane, Peter Venner, I. Tannock, Anil Kapoor, Bernhard J. Eigl, Aaron R. Hansen, Piotr Czaykowski, (unknown), Naveen S. Basappa	4
2	The impact of baseline serum testosterone and duration of first-line androgen deprivation therapy on the efficacy of docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC). 2014 ·Journal of Clinical Oncology ·Robert J. van Soest, Mario A. Eisenberger, Florence Mercier, I. Tannock, Ronald de Wit	1
3	From trial to practice: The Princess Margaret Hospital (PMH) experience with docetaxel and prednisone for men with metastatic castration resistant prostate cancer (mCRPC). 2013 ·Journal of Clinical Oncology ·Arnoud J. Templeton, Lisa Wang, Francisco Vera-Badillo, (unknown), (unknown), Raya Leibowitz‐Amit, Jennifer J. Knox, Malcolm J. Moore, Srikala S. Sridhar, Anthony M. Joshua, I. Tannock	0
4	A prospective study examining PROs and other geriatric outcomes in older adults with prostate cancer undergoing chemotherapy. 2013 ·Journal of Clinical Oncology ·(unknown), Salman Aziz, (unknown), Henriette Breunis, Anthony M. Joshua, I. Tannock, Shabbir M.H. Alibhai	1
5	1869 UTILIZATION AND IMPACT OF PERI-OPERATIVE CHEMOTHERAPY FOR MUSCLE-INVASIVE BLADDER CANCER: A POPULATION-BASED OUTCOMES STUDY 2013 ·The Journal of Urology ·D. Robert Siemens, Gavin Li, (unknown), I. Tannock, (unknown), Weidong Kong, William J. Mackillop, (unknown)	1
6	Abstract P2-05-12: Effects of de-escalated bisphosphonate therapy on bone turnover or metastasis markers and their correlation with risk of skeletal related events – A biomarker analysis in conjunction with the REFORM study. 2012 ·Cancer Research ·(unknown), Haidong Zhao, Sasha Mazzarello, Ranjeeta Mallick, Eitan Amir, I. Tannock, (unknown)	1
7	Evaluating the value of continuing docetaxel and prednisone (DP) beyond 10 cycles in men with metastatic castration-resistant prostate cancer (mCRPC). 2011 ·Journal of Clinical Oncology ·Gregory R. Pond, Andrew J. Armstrong, Brian Wood, Matthew Brookes, L. Leopold, William R. Berry, Ronald de Wit, Mario A. Eisenberger, I. Tannock, Guru Sonpavde	1
8	Adoption of neoadjuvant (NACT) and adjuvant chemotherapy (ACT) for bladder cancer: A population-based study. 2011 ·Journal of Clinical Oncology ·Christopher M. Booth, D. Robert Siemens, I. Tannock, Yingwei Peng, (unknown), (unknown)	2
9	Dose escalation of gemcitabine concomitant with radiation and cisplatin for nonsmall cell lung cancer 2010 ·Cancer ·Felix Momm, (unknown), I. Tannock, Martin Schumacher, J. Hasse, Michael Henke	1
10	Impact of 12 months of androgen-deprivation therapy (ADT) on cognitive function in men with nonmetastatic prostate cancer (PC): A matched cohort study. 2010 ·Journal of Clinical Oncology ·(unknown), (unknown), Gary Naglie, I. Tannock, George Tomlinson, Narhari Timilshina, (unknown), Neil Fleshner, Padraig Warde, S. Duff Canning	1
11	Use of changes in serum alkaline phosphatase to predict survival independent of PSA changes in men with castration-resistant prostate cancer and bone metastasis receiving chemotherapy: A retrospective analysis of the TAX327 trial. 2010 ·Journal of Clinical Oncology ·Gregory R. Pond, Guru Sonpavde, William R. Berry, Rianne de Wit, Andrew J. Armstrong, Mario A. Eisenberger, I. Tannock	2
12	Mature results of a randomized phase II study of OGX-011 in combination with docetaxel/prednisone versus docetaxel/prednisone in patients with metastatic castration-resistant prostate cancer 2009 ·Journal of Clinical Oncology ·(unknown), Sébastien J. Hotte, Evan Y. Yu, Daniel C. Tu, Bernhard J. Eigl, I. Tannock, Fred Saad, Scott North, Joseph D. Powers, E. Eisenhauer	23
13	A randomized phase II study of OGX-011 in combination with docetaxel and prednisone or docetaxel and prednisone alone in patients with metastatic hormone refractory prostate cancer (HRPC) 2007 ·Journal of Clinical Oncology ·(unknown), Sébastien J. Hotte, Evan Y. Yu, Bernhard J. Eigl, I. Tannock, Fred Saad, Scott North, Joseph D. Powers, E. Eisenhauer	9
14	The effects of the anti-cancer drugs, methotrexate and 5-fluorouracil, on cognitive function in mice 2006 ·Pharmacology Biochemistry and Behavior ·Gordon Winocur, Janette L. Vardy, Malcolm A. Binns, Lígia Regina Franco Sansigolo Kerr, I. Tannock	150
15	Is physical function affected by androgen deprivation therapy (ADT) in men with non-metastatic prostate cancer? 2006 ·Journal of Clinical Oncology ·Sven Gogov, Firasat Hussain, Gary Naglie, I. Tannock, Neil Fleshner, Murray Krahn, S. Duff Canning, Padraig Warde, (unknown)	0
16	A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC) 2004 ·Journal of Clinical Oncology ·Mario A. Eisenberger, Ronald de Wit, (unknown), I. Bodrogi, A Płużańska, K.N. Chi, Stéphane Oudard, (unknown), Nicholas D. James, I. Tannock	23
17	New perspectives in combined radiotherapy and chemotherapy treatment 1994 ·Lung Cancer ·I. Tannock	5
18	How American oncologists treat breast cancer: an assessment of the influence of clinical trials. 1991 ·Journal of Clinical Oncology ·(unknown), Margaret Moore, I. Tannock	45
19	How American oncologists treat breast cancer: An assessment of the influence of clinical trials 1991 ·Maturitas ·(unknown), Melissa M. Moore, I. Tannock	11
20	Experimental models of bladder cancer: a critical review. 1986 ·PubMed ·Derek Raghavan, F.M.J. Debruyne, H.W. Herr, D. Jocham, Tadao Kakizoe, (unknown), A A Sandberg, I. Tannock	14

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact